Suyanee Thongchot

Dr. Suyanee Thongchot

Department of Immunology, and Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT), Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2021 in Cells
Verified
Journal Article
Open access
PDF file
Alessandra FerraresiAlessandra Ferraresi
Alessandra Ferraresi
Andrea EspositoAndrea Esposito
Andrea Esposito
CGCarlo Girone
Carlo Girone
LVLetizia Vallino
Letizia Vallino
SASalwa Amreen
Salwa Amreen
Ciro IsidoroCiro Isidoro
Ciro Isidoro
Background: Ovarian cancer progression and invasiveness are promoted by a range of soluble factors released by cancer cells and stromal cells within the tumor microenvironment. Our previous studies demonstrated that resveratrol (RV), a nutraceutical and caloric restriction mimetic with tumor-suppressive properties, counteracts cancer cell motility induced by stromal IL-6 by upregulating autophagy. Lysophosphatidic acid (LPA), a bioactive phospholipid that shows elevated levels in the tumor microenvironment and the ascites of ovarian cancers, stimulates the growth and tissue invasion of cancer cells. Whether LPA elicits these effects by inhibiting autophagy and through which pathway and whether RV can counteract the same remain obscure. Aims: To investigate the molecular pathways involved in LPA-induced ovarian cancer malignancy, particularly focusing on the role of autophagy, and the ability of RV to counteract LPA activity. Results: LPA stimulated while RV inhibited ovarian cancer cell migration. Transcriptomic and bioinformatic analyses showed an opposite regulation by LPA and RV of genes linked to epithelial-to-mesenchymal transition (EMT) and autophagy with involvement of the PI3K-AKT, JAK-STAT and Hedgehog (Hh) pathways. LPA upregulated the Hh and EMT members GLI1, BMI-1, SNAIL-1 and TWIST1 and inhibited autophagy, while RV did the opposite. Similar to the inhibitors of the Hh pathway, RV inhibited LPA-induced cancer cell migration and 3D growth of ovarian cancer cells. BMI-1 silencing prevented LPA-induced EMT, restored autophagy and hampered cell migration, resembling the effects of RV. TCGA data analyses indicated that patients with low expression of Hh/EMT-related genes together with active autophagy flux tended to have a better prognosis and this correlates with a more effective response to platinum therapy. In in vitro 3D spheroids, LPA upregulated BMI-1, downregulated autophagy and inhibited platinum toxicity while RV and Hh inhibitors restored autophagy and favored BAX-mediated cell death in response to platinum. Conclusions: By inhibiting the Hh pathway and restoration of autophagy, RV counteracts LPA-induced malignancy, supporting its inclusion in the therapy of ovarian cancer for limiting metastasis and chemoresistance.

1 March 2021 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
STSuyanee Thongchot
Suyanee Thongchot
PJPranisa Jamjuntra
Pranisa Jamjuntra
STSuwanit Therasakvichya
Suwanit Therasakvichya
MWMalee Warnnissorn
Malee Warnnissorn
Alessandra FerraresiAlessandra Ferraresi
Alessandra Ferraresi
CTChanitra Thuwajit
Chanitra Thuwajit
The tumor microenvironment composed of a mixture of stromal cells and their secretions has a marked impact on cancer progression. In particular, soluble factors and metabolites contribute to malignancy through the dysregulation of autophagy in cancer cells. The present study investigated the effects of ovarian cancer‑associated fibroblasts (OVCAFs) with their secretory substances on the autophagy and migration of ovarian cancer cells. The conditioned‑medium (CM) of OVCAFs isolated from fresh human ovarian cancer tissues was analyzed for the levels of 27 common cytokines/chemokines using a cytokine array. Autophagy in cancer cells was assessed by determining the expression of the vacuolar form of LC3 by western blot analysis and immunofluorescence. Cancer cell migration was assessed by Transwell migration assay. Interleukin (IL)‑8 was found to be the most highly upregulated cytokine among the cytokines/chemokines found in the OVCAF‑CM. The role of IL‑8 in ovarian cancer cell migration and its mechanistic link with autophagy was investigated. Recombinant human IL‑8 (rhIL‑8) stimulated the migration of SKOV3 and Kuramochi ovarian cancer cells, and concurrently downregulated basal autophagy, in concentration‑dependent manner. Compared to the CM of control counterpart normal fibroblasts isolated from benign ovaries (OVNF‑CM), the CM from 3 OVCAF isolates (namely, OVCAF‑9, ‑20 and ‑43) exerted effects similar to rhIL‑8 on both cancer cell lines. The pharmacological induction of autophagy with rapamycin or metformin attenuated the pro‑migratory effects of IL‑8. Neutralizing anti‑IL‑8 antibody counteracted the inhibitory effect of OVCAF‑CM on basal autophagy. On the whole, the present study highlights the involvement of IL‑8 released by CAFs in the ovarian tumor microenvironment in promoting cancer cell migration through the suppression of autophagy.

21 March 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
STSuyanee Thongchot
Suyanee Thongchot
NJNiphat Jirapongwattana
Niphat Jirapongwattana
PLPiriya Luangwattananun
Piriya Luangwattananun
WCWannasiri Chiraphapphaiboon
Wannasiri Chiraphapphaiboon
NCNisa Chuangchot
Nisa Chuangchot
CTChanitra Thuwajit
Chanitra Thuwajit
Dendritic cell (DC)–based T-cell activation is an alternative immunotherapy in breast cancer. The anti-programmed death ligand 1 (PD-L1) can enhance T-cell function. Nucleolin (NCL) is overexpressed in triple-negative breast cancer (TNBC). The regulation of PD-L1 expression through autophagy and the anti–PD-L1 peptide to help sensitize T cells for NCL-positive TNBC cell killing has not been evaluated. Results showed the worst clinical outcome in patients with high NCL and PD-L1. Self-differentiated myeloid-derived antigen-presenting cells reactive against tumors presenting NCL or SmartDCs-NCL producing GM-CSF and IL-4, could activate NCL-specific T cells. SmartDCs-NCL plus recombinant human ribosomal protein substrate 3 (RPS3) successfully induced maturation and activation of DCs characterized by the reduction of CD14 and the induction of CD11c, CD40, CD80, CD83, CD86, and HLA-DR. Interestingly, SmartDCs-NCL plus RPS3 in combination with anti–PD-L1 peptide revealed significant killing activity of the effector NCL-specific T cells against NCLHigh/PD-L1High MDA-MB-231 and NCLHigh/PD-L1High HCC70 TNBC cells at the effector: a target ratio of 5:1 in 2-D and 10:1 in the 3-D culture system; and increments of IFNγ by the ELISpot assay. No killing effect was revealed in MCF-10A normal mammary cells. Mechanistically, NCL-specific T-cell–mediated TNBC cell killing was through both apoptotic and autophagic pathways. Induction of autophagy by curcumin, an autophagic stimulator, inhibited the expression of PD-L1 and enhanced cytolytic activity of NCL-specific T cells. These findings provide the potential clinical approaches targeting NCLHigh/PD-L1High TNBC cells with NCL-specific T cells in combination with a PD-L1 inhibitor or autophagic stimulator.

1 January 2020 in Journal of Cancer
Verified
Journal Article
Open access
SYSupaporn Yangngam
Supaporn Yangngam
STSuyanee Thongchot
Suyanee Thongchot
APAnanya Pongpaibul
Ananya Pongpaibul
KVKulthida Vaeteewoottacharn
Kulthida Vaeteewoottacharn
SPSomchai Pinlaor
Somchai Pinlaor
CTChanitra Thuwajit
Chanitra Thuwajit
Interleukin 33 (IL-33) promotes cholangiocarcinoma (CCA) genesis in a mouse model, however, its function in human CCA has not been clearly understood. This study was aimed to investigate IL-33 level in CCA tissues and its clinicopathological correlations. The results revealed that IL-33 was found in both cancer cells and stromal cancer-associated fibroblast (CAFs) staining patterns which were divided into high (CH) and low level (CL) in cancer cells; and presence (FP) and absence (FA) in CAFs. Kaplan-Meier analysis showed that patients in the CL group were significantly correlated with a short 2-year survival time (P = 0.027). The CL/FP group had a shorter survival time compared to the other groups with statistical significance for 2-year (P = 0.030) and 5-year (P = 0.023) survivals. In contrast, CH/FP patients had significantly greater 2-year (P = 0.003) and 5-year (P = 0.003) survivals. Univariate and multivariate analysis confirmed that CL/FP was a significantly independent risk factor whereas CH/FP was a significant protective factor in CCA patients. High IL-33 expressing CCA cells had low migration, but they showed increased migration when IL-33 expression was knocked down. The low level of recombinant human IL-33 (rhIL-33) (0.002 - 2 ng/ml) could promote CCA cell migration, in contrast to the suppressive effect at a high dose (20 - 200 ng/ml). In conclusion, the combination of high IL-33 level in cancer cells and CAFs is a potentially good prognosis marker in CCA patients. The in vitro migration suppressive effect of IL-33 may be the potential mechanism supporting its role as a good prognostic marker in CCA patients. The obtained results strengthen IL-33 as a promising predictor and therapeutic target for CCA.

21 January 2020 in Applied Biological Chemistry
Verified
Journal Article
Open access
PDF file
WPWisarut Payoungkiattikun
Wisarut Payoungkiattikun
AJAnupong Joompang
Anupong Joompang
STSuyanee Thongchot
Suyanee Thongchot
BNBoonpob Nowichai
Boonpob Nowichai
NJNisachon Jangpromma
Nisachon Jangpromma
SKSompong Klaynongsruang
Sompong Klaynongsruang
Although several explications of anti-inflammatory therapeutic substances for treating inflammatory-related diseases have been broadly discussed within the last few decades, peptide-based compounds display the potential to be novel inflammation treatment agents. Here, we evaluated the anti-inflammatory activity and other inflammation-associated activities, including anti-oxidative stress and anti-apoptosis properties, of the cationic peptides KT2 and RT2. Nitric oxide (NO) and other inflammatory markers were evaluated in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells co-incubated with peptides. The levels of interrelated gene and protein expressions were quantified. Peptides formed complexes with LPS and displayed anti-inflammatory properties by reducing NO and pro-inflammatory cytokine production in inflamed RAW 264.7 cells. These peptides also exhibit a strong suppressive effect on mRNA expression levels of inducible nitric oxide synthase, tumor necrosis factor-α, signal transducer and activator of transcription 1, c-Jun N-terminal protein kinase (JNK)-1, nuclear factor kappa B (NF-κB), and p38 mitogen-activated protein kinase (MAPK), which affects the decay of phosphorylated JNK-1, p38 MAPK, and NF-κB p65 protein expression. Both peptides induce up-regulation of anti-inflammatory mRNA and protein expression levels of extracellular signal-regulated kinase and mRNA expression levels of MAPK phosphatase-1. Also, the production of reactive oxygen species was observed to be markedly reduced. Furthermore, peptides exhibited an anti-apoptotic property. To our knowledge, this is the first report of the multi-functional peptides KT2 and RT2 exerting broad biological activity related to anti-inflammatory effects. These peptides have potential for delivering a medical method for the handling of inflammation-related diseases.

29 March 2024 in Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
Alessandra FerraresiAlessandra Ferraresi
Alessandra Ferraresi
STSuyanee Thongchot
Suyanee Thongchot
Ciro IsidoroCiro Isidoro
Ciro Isidoro
Alessandra Ferraresi, Suyanee Thongchot, Ciro Isidoro. J Cancer Prev 2024;29:1-5. https://doi.org/10.15430/JCP.24.001